Roche CEO won't spurn rare-disease biz; Lupin bets on new generic TriCor launches;

roche building

@FiercePharma: Tuesday's top news: Astellas + Medivation prostate-cancer prodigy Xtandi shines in pre-chemo. Article | Follow @FiercePharma

@EricPFierce: Amarin cuts 50% of its staff after FDA panel vote leaves Vascepa extension high and dry. News | Follow @EricPFierce

@CarlyHFierce: ICYMI: Reckitt Benckiser weighs pharma-unit sale as Suboxone slumps. Yesterday's story | Follow @CarlyHFierce

> Roche ($RHHBY) CEO Severin Schwan said he wouldn't rule out a move into rare diseases, but he wouldn't comment on whether the company is interested in buying Alexion Pharmaceuticals ($ALXN) or BioMarin Pharmaceuticals ($BMRN) as rumored. Report

> India's Lupin eyes U.S. growth for its cholesterol drug Antara, a version of AbbVie's ($ABBV) TriCor, with the launch of two new dosage strengths. Report

> Roche's cancer drug Avastin boosted overall survival in women with ovarian cancer, according to data from a U.K. study. Report

> A GlaxoSmithKline ($GSK) consumer health plant in Aiken, SC, stopped operating yesterday as authorities and firefighters searched for the source of a gas leak. Report

> Increasingly drug-resistant tuberculosis spreads quickly, threatening recent progress in the fight against the disease, the World Health Organization (WHO) says. Report

Medical Device News

@FierceMedDev: Siemens skirts whistleblower suit over alleged Chinese kickbacks. News | Follow @FierceMedDev

> Thermo Fisher soars on diagnostics as blockbuster Life deal awaits. Story

> Illumina dazzles with Q3 diagnostics expansion and revenue growth. Report

> Myriad sues BioReference Laboratories alleging BRCA cancer test patent violation. Item

> Monteris bags $13M for laser neurosurgery tech. News

Biotech News

@FierceBiotech: New feature: The top 10 biotech IPOs of 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Problem with Lilly: even if they get new diabetes drugs approved--everyone is piling into the same niches. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Ariad's Iclusig agony has put a hold on its planned move to Cambridge's biotech hotbed. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: This week's issue of FierceBiotech Research is out. Check it out | Follow @EmilyMFierce

> Alzheimer's team tackles a daunting R&D field with a new game plan. News

> Is Roche going to do some big rare disease drug deals? More

> FDA review heralds first-in-class status for Gilead's hep C drug sofosbuvir. Story

> Merck's beleaguered R&D division wins its second 'breakthrough' title at FDA. Article

Drug Delivery News

@MichaelGFierce: New method allows first-ever delivery of highly toxic cancer drug. More | Follow @MichaelGFierce

> Molecular 'grenades' from GenSpera reel in PhI liver cancer success. Story

> Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery. Article

> Study: Heated chemo-delivering nanoparticles kill 95% of ovarian cancer cells. Report

> Implantable, light-sensitive hydrogel could help treat diabetes. Item

Diagnostics News

@MarkHFierce: The top med tech VC investments of Q3 are all late-stage companies. Click for all the juicy details. FierceMedicalDevices feature | Follow @MarkHFierce

> Myriad targets 3rd company with BRCA cancer test lawsuit. News

> King's College London team make strides toward rapid sepsis test. More

> QuantuMDx gets $1.6M government grant for superfast, portable TB test. Story

> Precipio grabs $1.7M to grow cancer Dx services business with Yale connection. Article

> Roche to close 454 Life Sciences as it reduces gene sequencing focus. Report

And Finally... The FDA asked dog owners for help tracking deaths and illnesses tied to jerky treats. Report